用于癌症治疗的细胞周期蛋白依赖性激酶9小分子抑制剂
Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy.
作者信息
Alsfouk Aisha
机构信息
Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
出版信息
J Enzyme Inhib Med Chem. 2021 Dec;36(1):693-706. doi: 10.1080/14756366.2021.1890726.
Cyclin-dependent kinase 9 (CDK9) plays a vital role in transcription through regulation of short-lived anti-apoptotic genes required for cancer cell survival. Therefore, targeting CDK9 with small molecule inhibitors has emerged as a potential cancer therapy. This article reviews the most recent CDK9 patent literature (2012-2020) related to small molecule inhibitors in cancer along with their selectivity profile and biological results in preclinical studies.
细胞周期蛋白依赖性激酶9（CDK9）通过调节癌细胞存活所需的短寿命抗凋亡基因在转录过程中发挥重要作用。因此，用小分子抑制剂靶向CDK9已成为一种潜在的癌症治疗方法。本文综述了与癌症小分子抑制剂相关的最新CDK9专利文献（2012 - 2020年）及其在临床前研究中的选择性概况和生物学结果。
Zotero 插件